시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 PD-1 저항성 두경부암 시장 보고서(2025년)
PD-1 Resistant Head And Neck Cancer Global Market Report 2025
상품코드 : 1730984
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,183,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,938,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,692,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 PD-1 저항성 두경부암 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 예측기간에 예상되는 성장은 바이오마커 연구 증가, 새로운 치료법 개발, 개별회 의료 어프로치 증가, 암 연구개발 투자 증가, 규제 당국에 의한 승인 증가 등 여러 요인으로 인한 것입니다.

PD-1 저항성 두경부암 시장의 성장은 인지도의 향상과 조기 진단이 견인할 것으로 예측됩니다. PD-1 저항성 두경부암의 조기 발견은 대체 요법에 의한 적시 개입을 가능하게 하고, 치료 성적의 향상과 생존율의 향상으로 연결됩니다. 그 결과, 인지도의 향상과 조기 진단이 PD-1 저항성 두경부암 시장 성장을 뒷받침하고 있습니다.

주요 기업은 개인화 암 치료를 포함한 치료 저항성을 극복하기 위한 혁신적인 접근법에 주력하고 있습니다. 2024년 11월, 미국의 바이오테크놀러지 기업인 CEL-SCI Corporation은 두경부암 연구에 PD-L1 바이오마커를 포함하는 것을 FDA로부터 승인되었습니다. 이것은 앞의 제3상 임상시험의 양호한 결과에 계속되는 것으로, 개별화 암 치료에 있어서의 중요한 한 걸음이며, PD-1 저항성 암을 보다 잘 관리하기 위한 새로운 희망이 됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

PD-1 resistant head and neck cancer refers to head and neck squamous cell carcinomas (HNSCCs) that do not respond to therapies aimed at targeting the programmed death-1 (PD-1) pathway. PD-1 is an immune checkpoint protein that, when blocked, can boost the body's immune system to fight cancer cells. However, some HNSCCs develop resistance to these therapies, either from the beginning (de novo resistance) or after initially responding (acquired resistance).

The primary treatments for PD-1-resistant head and neck cancer include chemotherapy, radiation therapy, surgery, and targeted therapy. Chemotherapy involves using drugs to destroy cancer cells or prevent their growth. These drugs can be given orally or intravenously and work by targeting rapidly dividing cells, including cancer cells. Chemotherapy is often combined with other treatments to increase its effectiveness. Treatment is applied at various stages, such as early stage, locally advanced stage, and metastatic stage. These therapies are used in the treatment of conditions such as squamous cell carcinoma, adenocarcinoma, nasopharyngeal carcinoma, and throat cancer, with end-users including hospitals, cancer research centers, and clinics.

The PD-1-resistant head and neck cancer market research report is one of a series of new reports from The Business Research Company that provides PD-1-resistant head and neck cancer market statistics, including PD-1-resistant head and neck cancer industry global market size, regional shares, competitors with a PD-1-resistant head and neck cancer market share, detailed PD-1-resistant head and neck cancer market segments, market trends and opportunities, and any further data you may need to thrive in the PD-1-resistant head and neck cancer industry. This PD-1-resistant head and neck cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The PD-1 resistant head and neck cancer market size has grown rapidly in recent years. It will grow from $1.28 billion in 2024 to $1.43 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth observed during the historic period can be attributed to several factors, including a rise in prevalence, greater adoption of immunotherapy, an increase in clinical trial activities, growing resistance to PD-1 inhibitors, and a heightened focus on combination therapies.

The PD-1 resistant head and neck cancer market size is expected to see rapid growth in the next few years. It will grow to $2.20 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth projected for the forecast period can be attributed to several factors, such as an increase in biomarker research, the development of new therapies, a rise in personalized medicine approaches, growing investment in oncology R&D, and more regulatory approvals. Key trends during this period include the advancement of combination therapies, progress in precision oncology, the adoption of next-generation sequencing, enhanced research on the tumor microenvironment, and the use of AI-driven drug discovery.

The growth of the PD-1-resistant head and neck cancer market is expected to be driven by increasing awareness and early diagnosis. The growing recognition of cancer and improvements in screening programs, healthcare initiatives, and diagnostic technologies are contributing to earlier detection and treatment. Early detection of PD-1-resistant head and neck cancer allows for timely interventions with alternative therapies, leading to better treatment outcomes and higher survival rates. For example, in January 2025, The National Health Service (NHS) in the UK reported that 120,958 of the 206,038 common cancers diagnosed between September 2023 and August 2024 were detected at an early stage. This represents 58.7% of diagnoses, a 2.7 percentage point increase compared to pre-pandemic levels, equating to an estimated additional 7,000 patients diagnosed early. As a result, the rise in awareness and early diagnosis is propelling market growth for PD-1-resistant head and neck cancer.

Major companies are focusing on innovative approaches to overcome treatment resistance, such as personalized cancer therapies. These treatments are tailored to a patient's genetic profile, tumor characteristics, and immune response, offering more precise and effective care. For instance, in November 2024, CEL-SCI Corporation, a US-based biotechnology company, gained FDA approval to include the PD-L1 biomarker in a head and neck cancer study. The study, which will begin in early 2025, will focus on newly diagnosed patients with low PD-L1 expression and no lymph node involvement to assess the safety and effectiveness of Multikine (Leukocyte Interleukin, Injection). This follows positive results from a previous Phase 3 trial, marking an important step in personalized cancer treatment and offering new hope for better managing PD-1-resistant cancers.

In October 2024, Exelixis Inc., a US-based biotech company, entered into a partnership with Merck & Co. Inc. to advance cancer treatment. This collaboration aims to test combination therapies for head and neck cancer and renal cell carcinoma. The agreement includes trials of KEYTRUDA combined with Exelixis' therapy for head and neck cancer and WELIREG for renal cell carcinoma. As part of the deal, Merck will supply KEYTRUDA for Exelixis' Phase 3 STELLAR-305 trial, targeting PD-L1-positive HNSCC, while both companies will co-fund trials for renal cell carcinoma. The goal of this partnership is to enhance treatment options by combining immunotherapy with targeted therapy.

Major players in the PD-1 resistant head and neck cancer market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GSK plc, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, Coherus BioSciences Inc., Akeso Biopharma, Rakuten Medical Inc., PDS Biotechnology Corporation, LARVOL, Nanobiotix, ALX Oncology Holdings Inc., RAPT Therapeutics Inc., and Immutep Limited.

North America was the largest region in the PD-1 resistant head and neck cancer market 2024. The regions covered in PD-1-resistant head and neck cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the PD-1-resistant head and neck cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The PD-1-resistant head and neck cancer market consists of revenues earned by entities by providing services such as diagnostic testing, combination therapies, genomic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The PD-1-resistant head and neck cancer market also includes sales of diagnostic tests, imaging services, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

PD-1 Resistant Head And Neck Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pd-1 resistant head and neck cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pd-1 resistant head and neck cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pd-1 resistant head and neck cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. PD-1 Resistant Head And Neck Cancer Market Characteristics

3. PD-1 Resistant Head And Neck Cancer Market Trends And Strategies

4. PD-1 Resistant Head And Neck Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global PD-1 Resistant Head And Neck Cancer Growth Analysis And Strategic Analysis Framework

6. PD-1 Resistant Head And Neck Cancer Market Segmentation

7. PD-1 Resistant Head And Neck Cancer Market Regional And Country Analysis

8. Asia-Pacific PD-1 Resistant Head And Neck Cancer Market

9. China PD-1 Resistant Head And Neck Cancer Market

10. India PD-1 Resistant Head And Neck Cancer Market

11. Japan PD-1 Resistant Head And Neck Cancer Market

12. Australia PD-1 Resistant Head And Neck Cancer Market

13. Indonesia PD-1 Resistant Head And Neck Cancer Market

14. South Korea PD-1 Resistant Head And Neck Cancer Market

15. Western Europe PD-1 Resistant Head And Neck Cancer Market

16. UK PD-1 Resistant Head And Neck Cancer Market

17. Germany PD-1 Resistant Head And Neck Cancer Market

18. France PD-1 Resistant Head And Neck Cancer Market

19. Italy PD-1 Resistant Head And Neck Cancer Market

20. Spain PD-1 Resistant Head And Neck Cancer Market

21. Eastern Europe PD-1 Resistant Head And Neck Cancer Market

22. Russia PD-1 Resistant Head And Neck Cancer Market

23. North America PD-1 Resistant Head And Neck Cancer Market

24. USA PD-1 Resistant Head And Neck Cancer Market

25. Canada PD-1 Resistant Head And Neck Cancer Market

26. South America PD-1 Resistant Head And Neck Cancer Market

27. Brazil PD-1 Resistant Head And Neck Cancer Market

28. Middle East PD-1 Resistant Head And Neck Cancer Market

29. Africa PD-1 Resistant Head And Neck Cancer Market

30. PD-1 Resistant Head And Neck Cancer Market Competitive Landscape And Company Profiles

31. PD-1 Resistant Head And Neck Cancer Market Other Major And Innovative Companies

32. Global PD-1 Resistant Head And Neck Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The PD-1 Resistant Head And Neck Cancer Market

34. Recent Developments In The PD-1 Resistant Head And Neck Cancer Market

35. PD-1 Resistant Head And Neck Cancer Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기